COLLEGE STATION, TX / ACCESSWIRE / June 7, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/) has announced a coherent protocol that it intends to execute to meet the Company's objective of producing a therapeutic cure for HIV as well as a planned protocol to address existing and future pandemics. This protocol has been defined as a result of the Company's collaboration with Intel Corporation in the field of applying computer analysis (Artificial Intelligence - A.I.) to accelerate health care discoveries and development. This collaboration includes exploring the interaction of monoclonal antibodies with viruses in 3-dimensional matrices. This opens new innovative pathways for drug discovery and development. The Company is actively exploring biotech partnerships, in the same way the Company is working with Intel Corporation, to advance and provide effective therapies and cures for existing and new viral illnesses. In combination with the Company's patented and clinically tested anti-HIV peptide ITV-1, the Company proposes a collaboration to fully implement the following protocol for developing and deploying therapeutics to address existing and future pandemics.

Enzolytics, Inc. (ENZC) is making a powerful move up the charts in recent days since a brief dip below the $0.10 mark. ENZC is a major league runner and powerhouse stock; over the past few months ENZC has seen a legendary run to recent highs of 0.958 per share as it completes the historic merger between BioClonetics and Enzolytics; the new biotech is getting noticed as its technology for producing fully human monoclonal antibodies is currently being employed to produce anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies for treating COVID-19. With each day of progression of the Coronavirus pandemic, the dire need for multiple active therapeutics becomes more evident. ENZC is a pioneer in using monoclonal antibodies for treating COVID-19. ENZC has partnered with Intel to publish a white paper titled, "Optimizing Empathetic A.I. to Cure Deadly Diseases," highlighting Intel's Artificial Intelligence Analytic tools and Enzolytic's innovative approach and groundbreaking contributions to create universal, durable, and broadly effective treatment targeting all virus variants.

An honest dialogue about a subject that is heartfelt to so many people around the world. Intel Corporation, and the team at Enzolytics, present a vision for the future of the Use of Artificial Intelligence for Social Good. As the pandemic has shown us, we are all in this together." It affects not only a person, family, community, or country but the entire world. Intel and Enzolytic's collaborative white paper(published earlier) titled "Optimizing Empathetic A.I. to Cure Deadly Diseases," [https://lnkd.in/dx5VKhg] We invite Government organizations, policymakers, biotechnology companies to join Enzolytics and Intel's vision of the future to find answers to the pandemic and transform healthcare.